Literature DB >> 15356812

Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities.

Ronald E Polk1, Christopher K Johnson, Donna McClish, Richard P Wenzel, Michael B Edmond.   

Abstract

Rates of fluoroquinolone resistance among Pseudomonas aeruginosa in hospitals are increasing, but interhospital variability is great. We sought to determine whether this variability correlated to fluoroquinolone use in hospitals and in the surrounding community. Hospital quinolone use in 1999 (24 hospitals) through 2001 (35 hospitals) was determined from billing records. The number of fluoroquinolone prescriptions within a 10-mile (approximately 16-km) radius of each hospital was determined for 1999 and 2000. Hospital fluoroquinolone use increased from 1999 through 2001, from 137 to 163 defined daily doses (DDD)/1000 patient-days (P=.01). The rate of community fluoroquinolone use also increased, from 2.3 to 2.8 DDD/1000 inhabitant-days (P<.001). Rates of fluoroquinolone-resistant P. aeruginosa increased from 29% in 1999 to 36% in 2001 (P=.003). Both community and hospital fluoroquinolone use were predictive of rates of fluoroquinolone-resistant P. aeruginosa. Levofloxacin was associated with resistance, but ciprofloxacin was not. Most of the variability in resistance rates is explained by volume of fluoroquinolone use, both in the hospital and the surrounding community.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15356812     DOI: 10.1086/422647

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  25 in total

1.  The use of antimicrobial agents after diagnosis of viral respiratory tract infections in hospitalized adults: antibiotics or anxiolytics?

Authors:  Kevin T Shiley; Ebbing Lautenbach; Ingi Lee
Journal:  Infect Control Hosp Epidemiol       Date:  2010-11       Impact factor: 3.254

Review 2.  Antimicrobial stewardship programs in health care systems.

Authors:  Conan MacDougall; Ron E Polk
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

3.  Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.

Authors:  John A Bosso; Patrick D Mauldin
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa.

Authors:  Keith S Kaye; Zeina A Kanafani; Ashley E Dodds; John J Engemann; Stephen G Weber; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 5.  Antimicrobial resistance in hospitals: how concerned should we be?

Authors:  Michael R Mulvey; Andrew E Simor
Journal:  CMAJ       Date:  2009-02-17       Impact factor: 8.262

6.  Challenges in measuring antibiotic consumption.

Authors:  Leigh Anne Hylton Gravatt; Amy L Pakyz
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

Review 7.  Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance.

Authors:  Vered Schechner; Elizabeth Temkin; Stephan Harbarth; Yehuda Carmeli; Mitchell J Schwaber
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

8.  Variation in hospital antibiotic prescribing practices for children with acute lymphoblastic leukemia.

Authors:  Brian T Fisher; Jeffrey S Gerber; Kateri H Leckerman; Alix E Seif; Yuan-Shung V Huang; Yimei Li; Tracey Harris; Kari Torp; Rheam Douglas; Ami Shah; Dana Walker; Richard Aplenc
Journal:  Leuk Lymphoma       Date:  2012-12-26

9.  Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?

Authors:  Ping-Feng Wu; Yi-Tsung Lin; Fu-Der Wang; Tsuey-Ching Yang; Chang-Phone Fung
Journal:  Infection       Date:  2018-03-20       Impact factor: 3.553

10.  The relative contribution of efflux and target gene mutations to fluoroquinolone resistance in recent clinical isolates of Pseudomonas aeruginosa.

Authors:  S A Dunham; C J McPherson; A A Miller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-01-23       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.